Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Macrogenics (MGNX) EBITDA Margin (2016 - 2025)

Macrogenics (MGNX) has disclosed EBITDA Margin for 14 consecutive years, with 34.27% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 431.0% to 34.27% in Q4 2025 year-over-year; TTM through Dec 2025 was 49.89%, a 7787.0% increase, with the full-year FY2025 number at 49.89%, down 525.0% from a year prior.
  • EBITDA Margin was 34.27% for Q4 2025 at Macrogenics, down from 23.11% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 436.88% in Q2 2023 to a low of 1686.45% in Q2 2024.
  • A 5-year average of 249.73% and a median of 158.98% in 2022 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: plummeted -212334bps in 2024, then surged 152344bps in 2025.
  • Macrogenics' EBITDA Margin stood at 410.55% in 2021, then soared by 104bps to 17.66% in 2022, then crashed by -2532bps to 429.51% in 2023, then skyrocketed by 91bps to 38.58% in 2024, then increased by 11bps to 34.27% in 2025.
  • Per Business Quant, the three most recent readings for MGNX's EBITDA Margin are 34.27% (Q4 2025), 23.11% (Q3 2025), and 163.02% (Q2 2025).